Metastatic behavior of breast cancer subtypes
- PMID: 20498394
- DOI: 10.1200/JCO.2009.25.9820
Metastatic behavior of breast cancer subtypes
Abstract
Purpose: Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected.
Methods: Patients with early-stage breast cancer diagnosed between 1986 and 1992 with archival tissue were included. Subtypes were defined as luminal A, luminal B, luminal/human epidermal growth factor receptor 2 (HER2), HER2 enriched, basal-like, and triple negative (TN) nonbasal. Distant sites were classified as brain, liver, lung, bone, distant nodal, pleural/peritoneal, and other. Cumulative incidence curves were estimated for each site according to competing risks methods. Association between the site of relapse and subtype was assessed in multivariate models using logistic regression.
Results: Median follow-up time among 3,726 eligible patients was 14.8 years. Median durations of survival with distant metastasis were 2.2 (luminal A), 1.6 (luminal B), 1.3 (luminal/HER2), 0.7 (HER2 enriched), and 0.5 years (basal-like; P < .001). Bone was the most common metastatic site in all subtypes except basal-like tumors. In multivariate analysis, compared with luminal A tumors, luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases. Basal-like tumors had a higher rate of brain, lung, and distant nodal metastases but a significantly lower rate of liver and bone metastases. TN nonbasal tumors demonstrated a similar pattern but were not associated with fewer liver metastases.
Conclusion: Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse.
Similar articles
-
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.Breast Cancer Res. 2011 Sep 13;13(5):R87. doi: 10.1186/bcr2944. Breast Cancer Res. 2011. PMID: 21914172 Free PMC article.
-
Breast cancer subtypes and the risk of local and regional relapse.J Clin Oncol. 2010 Apr 1;28(10):1684-91. doi: 10.1200/JCO.2009.24.9284. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194857
-
Patterns of breast cancer relapse in accordance to biological subtype.J Cancer Res Clin Oncol. 2018 Jul;144(7):1347-1355. doi: 10.1007/s00432-018-2644-2. Epub 2018 Apr 19. J Cancer Res Clin Oncol. 2018. PMID: 29675790
-
Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate.Cancers (Basel). 2021 Nov 25;13(23):5917. doi: 10.3390/cancers13235917. Cancers (Basel). 2021. PMID: 34885027 Free PMC article. Review.
-
Classifying Breast Cancer Metastasis Based on Imaging of Tumor Primary and Tumor Biology.Diagnostics (Basel). 2023 Jan 25;13(3):437. doi: 10.3390/diagnostics13030437. Diagnostics (Basel). 2023. PMID: 36766541 Free PMC article. Review.
Cited by
-
Update on triple-negative breast cancer: prognosis and management strategies.Int J Womens Health. 2012;4:511-20. doi: 10.2147/IJWH.S18541. Epub 2012 Sep 24. Int J Womens Health. 2012. PMID: 23071421 Free PMC article.
-
Identification of markers associated with brain metastasis from breast cancer through bioinformatics analysis and verification in clinical samples.Gland Surg. 2021 Mar;10(3):924-942. doi: 10.21037/gs-20-767. Gland Surg. 2021. PMID: 33842237 Free PMC article.
-
Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.Sci Adv. 2021 Mar 3;7(10):eabe8671. doi: 10.1126/sciadv.abe8671. Print 2021 Mar. Sci Adv. 2021. PMID: 33658202 Free PMC article.
-
Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer.Front Pharmacol. 2020 Aug 7;11:1211. doi: 10.3389/fphar.2020.01211. eCollection 2020. Front Pharmacol. 2020. PMID: 32848800 Free PMC article.
-
Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.Breast Cancer Res. 2022 Oct 25;24(1):70. doi: 10.1186/s13058-022-01569-1. Breast Cancer Res. 2022. PMID: 36284362 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous